YHYaomin Hu

Yaomin Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaomin Hu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Yurong Weng

    Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    9 shared publications
  • Tingting Han

    Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    6 shared publications
  • Jie Cao

    Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    5 shared publications
  • Mingyu Zhu

    Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    5 shared publications
  • Ting Zhang

    Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    5 shared publications
  • Hongxia Liu

    Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    4 shared publications

Latest Publications

  • Triglyceride-related metabolic indices and low relative muscle mass: a cross-sectional analysis of SMILE and NHANES

    by Ting Liu, Ning Chen, Rui Du, Mingyu Zhu, Jie Cao, Qin Zhu, Xiaolin Xu, Yunjie Li, Xian Jin, Yurong Weng, et al.

  • Open Access

    Akkermansia muciniphila and Its Bioactive Derivatives: Emerging Regulators of Healthy Aging

    by Ting Zhang, Jinyuan Niu, Xiaoyu Hu, Zhiang Hu, Yuan Gao, Jialiang Liu, Ning Chen, Yaomin Hu

    The global aging trend underscores the urgent need for innovative interventions against aging‐related decline. Accumulating evidence identifies Akkermansia muciniphila ( A. muciniphila ) as a key gut microbiota regulator of aging, with its depletion associated with age‐related diseases (ARDs), whereas its abundance is enriched in healthy centenarians. This review summarized current evidence linking A. muciniphila to aging, examining their causal relationship, the roles of its bioactive derivatives, underlying mechanisms in aging and ARDs, findings from human clinical trials, and challenges in therapeutic translation. Clinically, A. muciniphila depletion correlated with aging and various ARDs, while its supplementation effectively ameliorated neurodegenerative disorders, metabolic dysfunction, musculoskeletal decline, intestinal barrier dysfunction, and atherosclerosis. Mechanistically, A. muciniphila and its derivatives (Amuc_1100, Amuc_1409, extracellular vesicles, and metabolites such as SCFAs) exerted anti‐aging effects by enhancing intestinal barrier function, maintaining metabolic homeostasis, suppressing chronic inflammation, and modulating immune function, ultimately improving glucolipid metabolism, insulin sensitivity, cognitive function, musculoskeletal health, and vascular health. Emerging clinical trials further demonstrated its translational potential in ameliorating age‐related sarcopenia, metabolic dysfunction, and respiratory symptoms. Despite promising preclinical and clinical results, translational applications reserve challenges related to strain heterogeneity, antimicrobial resistance gene transfer risk, biosafety, production stability, and limited clinical validation in elderly populations. Future research should prioritize large‐scale clinical trials to establish optimal dosage, safety, and long‐term efficacy, while exploring combined microbiota‐targeted therapies. Harnessing the diverse benefits of A. muciniphila may enable novel strategies for promoting healthy aging.


  • Open Access

    From mouth to muscle: mechanistic and interventional perspectives on the tongue-coating microbiome in sarcopenia

    by Xin Zhao, Yurong Weng, Rong Huang, Yaomin Hu

    Sarcopenia, the progressive loss of skeletal muscle mass and function, needs upstream, low-burden tools for early detection and high-frequency monitoring,

  • Open Access

    Physical performance outweighs grip strength in predicting diabetes risk: evidence from a prospective cohort study

    by Mingyu Zhu, Qin Zhu, Hongxia Liu, Rui Du, Jie Cao, Ning Chen, Ting Liu, Ting Zhang, Tingting Han, Yurong Weng, et al.

    Diabetes represents a growing global public health burden. Traditional risk assessments based on static metabolic markers may not adequately reflect underl


  • Open Access

    Associations of serum bile acids and amino acids with low skeletal muscle mass among Chinese population: a cross-sectional study

    by Ting Zhang, Ning Chen, Ting Liu, Mingyu Zhu, Hongxia Liu, Tingting Han, Yurong Weng, Rong Huang, Yaomin Hu

    Sarcopenia, characterized by progressive muscle loss, burdens aging populations. While bile acids (BAs) in skeletal muscle mass (SMM) are poorly understood, the role of amino acids (AAs) remains debated. This study investigated the associations between serum BAs, AAs, and low SMM in Chinese adults. Among 2170 initially enrolled participants, 702 were finally analyzed. Participants were classified into low and normal SMM groups. Serum BAs and AAs were quantified by targeted LC-MS/MS. Nonlinear relationships were assessed using restricted cubic spline analysis. Mediation analysis was used to assess the mediating effects of metabolic factors. The prevalence of low SMM was 14.5% (females: 21.1% vs. males: 10.2%). Multivariable logistic regression identified that increased glycocholic acid (GCA, OR = 0.561, p = 0.030), glycolithocholic acid (GLCA, OR = 0.255, p < 0.001) and deoxycholic acid (DCA, OR = 0.444, p = 0.003) were independently associated with lower risk of low SMM in the fully adjusted model. Valine (OR = 0.646, p = 0.010) and leucine (OR = 0.680, p = 0.024) showed consistent protective effects against low SMM at physiological concentrations. Mediation analysis showed BMI mediated protective effects of GCA, valine and leucine (all p < 0.01), while creatinine/cystatin C ratio mediated leucine’s effect (p = 0.030). Notably, GLCA exhibited direct protection independent of metabolic mediators (both p < 0.01). This study identified specific BAs and AAs significantly correlated with preserved SMM, suggesting that modulating BA metabolism (particularly elevating GLCA) and maintaining optimal BCAA levels may be effective strategies for low SMM. GLCA’s direct protective effect supports exploring dietary or microbiota-targeted interventions. Individual metabolic profiles, such as BMI, should be incorporated into personalized sarcopenia management.


  • A nomogram model combining sarcopenic obesity and biomarkers to predict the risk of vascular stiffness

    by Wenwen Liu, Mingyu Zhu, Ziyi Wei, Ningxin Chen, Tingting Han, Ting Zhang, Yurong Weng, Yiling Fan, Yaomin Hu


  • Open Access

    Tas2r105 ameliorates gut inflammation, possibly through influencing the gut microbiota and metabolites

    by Xiucai Lan, Liang Ma, Jiaming Ma, Zhipeng Huang, Lingling Liu, Feng Li, Mingbang Wang, Yaomin Hu

    Inflammatory bowel disease (IBD) is an immune-mediated gastrointestinal disorder that significantly impacts the life quality of people worldwide. Genetic factors play crucial roles in the development of IBD. Tas2rs, members of the G protein-coupled receptor (GPCR) superfamily, are known for their roles in bitter taste perception. However, Tas2rs have also been identified in the gut, where they help sense luminal contents and regulate gastrointestinal hormones. Periodontal Tas2r105 has been shown to modulate innate immunity by interacting with metabolites produced by oral bacteria. In this study, we observed increased Tas2r105 in the inflammatory colons induced by dextran sulfate sodium salt (DSS). We also noted that α-gustducin, the α-subunit of GPCRs, is present in the intestine, and that α-gustducin knockout mice exhibit aggravated colitis. Based on these findings, we hypothesize that Tas2r105 may play a role in immune regulation during IBD pathogenesis. To test this hypothesis, we used Tas2r105 knockout (KO) mice in a colitis model. Our results show that the KO mice had significantly shorter colon length, more severe colon inflammation, and greater destruction of the gut barrier compared with control mice. We also observed increased recruitment of macrophages to the lamina propria mucosa in the KO mice. Microbiological analysis revealed a significant increase in Proteobacteria and Bacteroidota , with a concomitant decrease in Firmicutes after Tas2r105 knockout. Metabolomic analysis showed a significant reduction in lysophosphatidylethanolamine (LPE) levels in the KO mice, which is known to have anti-inflammatory effects. Based on these findings, we speculate that Tas2r105 may help protect the intestine from inflammation by influencing the gut microbiota composition and LPE production. IMPORTANCE: Increased Tas2r105 was detected in the inflamed colon of mice outside the tongue. Tas2r105 deletion aggravated mice colon colitis. Tas2r105 might alleviate mice colitis by downregulating the Proteobacteria and the Bacteroidota abundance in the colon. Lysophosphatidylethanolamine (LPE) might be the key metabolite that mediated the intestinal protection of Tas2r105.


  • Open Access

    Development and validation of a predicative model for identifying sarcopenia in Chinese adults using nutrition indicators (AHLC)

    by Xin Zhao, Pengdong Yan, Ningxin Chen, Tingting Han, Bin Wang, Yaomin Hu

    Background: Sarcopenia, a condition characterized by low muscle mass, plays a critical role in the health of older adults. Early identification of individuals at risk is essential to prevent sarcopenia-related complications. This study aimed to develop a predictive model using readily available clinical nutrition indicators to facilitate early detection.Methods: A total of 1,002 participants were categorized into two groups: 819 with normal skeletal muscle mass (SMM) and 183 with low muscle mass (sarcopenia). A predictive model was developed for sarcopenia risk via multivariate logistic regression, and its performance was assessed using four analyses: receiver operating characteristic (ROC) curve analysis, decision curve analysis (DCA), a nomogram chart, and external validation. These methods were used to evaluate the model’s discriminative ability and clinical applicability.Results: In the low-SMM group, more females (55.73% vs. 40.42%) and older individuals (median 61 vs. 55 years) were observed. These patients had lower albumin (41.00 vs. 42.50 g/L) and lymphocyte levels (1.60 vs. 2.02 × 109/L) but higher HDL (1.45 vs. 1.16 mmol/L) and calcium levels (2.24 vs. 2.20 mmol/L) (all p < 0.001). Using LASSO regression, we developed a nutritional AHLC (albumin + HDL cholesterol + lymphocytes + calcium) model for sarcopenia risk prediction. AUROC and DCA analyses, as well as nomogram charts and external validation, confirmed the robustness and clinical relevance of the AHLC model for predicting sarcopenia.Conclusion: Our study employs serum nutrition indicators to aid clinicians in promoting healthier aging. The AHLC model stands out for weight-independent evaluations. This novel approach could assess sarcopenia risk in the Chinese population, thereby enhancing aging and quality of life.


  • Open Access

    Sex differences in the association between chest computed tomography-defined sarcopenia and cardiovascular risk factors among inpatients

    by Xin Chen, Mingyu Zhu, Jie Cao, Didi Zuo, Zengai Chen, Yurong Weng, Hua Jiang, Yaomin Hu, \R\Nxin Chen

    Background: While sarcopenia has been found to be associated with increased risks of cardiovascular diseases (CVDs), evidence exploring sex-related differences remains insufficient. This study aimed to investigate the differences in how often sarcopenia occurs in each sex, as determined by skeletal muscle area (SMA) in chest CT images, and its association with CVD common risk factors.Methods: This cross-sectional study involved 1,340 inpatients from the Department of Geriatrics of Renji Hospital, affiliated to Shanghai Jiaotong University School of Medicine. Data on age, sex, body mass index (BMI), smoking status, disease history, and clinical parameters were collected. Sarcopenia was defined using chest CT images with a cut-off value of T12-SMA/height2 2/m2 in male patients and 2/m2 in female patients. Cardiovascular risk was assessed using the Framingham risk score (FRS). The association between T12-SMA/height2-defined sarcopenia and CVD risk factors by sex was evaluated using a multivariate logistic regression analysis.Results: The overall prevalence of T12-SMA/height2-defined sarcopenia (2/m2 for male patients, 2/m2 for female patients) was 54.03%, with 48.09% in male patients and 63.19% in female patients. The proportion of male patients with high CVD risk was greater than that of female patients. The multivariate analysis revealed that T12-SMA/height2-defined sarcopenia was independently associated with age (in male patients only), systolic blood pressure (SBP), cholesterol, and high-density lipoprotein cholesterol (HDL-C) among the six FRS cardiovascular risk indices.Conclusion: Our results suggest that T12-SMA/height2-defined sarcopenia was more prevalent in male patients than in female patients. Sarcopenia was associated with higher levels of SBP and HDL-C and lower levels of cholesterol. Increasing age had a more significant effect on CVD risk in male patients.


  • Mito-Tempo alleviates ox-LDL-provoked foam cell formation by regulating Nrf2/NLRP3 signaling

    by Zhenyu Huang, Zhaoli Zhou, Ying Ma, Yao-Min Hu

    Our previous studies have demonstrated that Mito-Tempol (also known as 4-hydroxy-Tempo), a mitochondrial reactive oxygen species scavenger, alleviates oxidized low-density lipoprotein (ox-LDL)-triggered foam cell formation. Given the effect of oxidative stress on activating the NOD-, LRR-, and pyrin domain-containing 3 (NLRP3) inflammasome, which promotes foam cell formation, we aimed to explore whether Mito-Tempo inhibits ox-LDL-triggered foam cell formation by regulating NLRP3 inflammasome. The results revealed that Mito-Tempo re-activated Nrf2 and alleviated macrophage foam cell formation induced by ox-LDL, whereas the effects were reversed by ML385 (a specific Nrf2 inhibitor). Mito-Tempo restored the expression and nuclear translocation of Nrf2 by decreasing ox-LDL-induced ubiquitination. Furthermore, Mito-Tempo suppressed ox-LDL-triggered NLRP3 inflammasome activation and subsequent pyroptosis, whereas the changes were blocked by ML385. Mito-Tempo decreased lipoprotein uptake by inhibiting CD36 expression and suppressed foam cell formation by regulating the NLRP3 inflammasome. Taken together, Mito-Tempo exhibits potent anti-atherosclerotic effects by regulating Nrf2/NLRP3 signaling.